{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:58:36Z","timestamp":1769849916315,"version":"3.49.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Low back pain affects around 619 million people globally and is the most prevalent musculoskeletal condition worldwide. Low back pain is often difficult to treat with traditional drug combinations, and opioids are prescribed for up to 60% of patients with debilitating low back pain. This study aimed at characterizing the analgesic effect of (2R,6R)-Hydroxynorketamine, an \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor dependent analgesic agent, alone or in combination with meloxicam in a murine lumbar disk puncture model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Male and female C57BL\/6J mice underwent lumbar disk puncture and developed tactile allodynia. At day 7 postoperatively, mice were randomized to receive intraperitoneal saline, (2R,6R)-Hydroxynorketamine, meloxicam or both drugs co-administered for 3 consecutive days. Analgesia was assessed at baseline and 24\u2005h following each injection using von Frey testing of both hind limbs and the area under the paw withdrawal curve (AUC<jats:sub>0\u22123d<\/jats:sub>) was determined. Brain, spinal cord, and dorsal root ganglion tissues were obtained for immunohistochemistry and western blot analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Prior to disk puncture paw withdrawal thresholds were 3.44\u2009\u00b1\u20090.51\u2005g before surgery and were reduced to 0.54\u2009\u00b1\u20090.38\u2005g at day 7 without a difference by sex; however, sex-specific responses were evident in other behavioral outcomes. EC<jats:sub>50<\/jats:sub> estimates for (2R,6R)-Hydroxynorketamine were 14.2\u2005mg\/kg (95% CI: 10.3\u2005mg\/kg to 19.7\u2005mg\/kg) in male and 16.9\u2005mg\/kg (95% CI: 12.8\u2005mg\/kg to 22.3\u2005mg\/kg) in female mice (<jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.637). (2R,6R)-Hydroxynorketamine plus meloxicam enhanced the analgesic effect on the AUC<jats:sub>0\u22123d<\/jats:sub> of meloxicam alone. (2R,6R)-Hydroxynorketamine analgesia was associated with increases in Glutamate receptor A1 &amp;amp; A2, p-Kv2.1, p-CaMKII and reduced BDNF protein ratios in the hippocampus, attenuated c-Fos in the spinal cord, and decreased BDNF at the dorsal root ganglion (DRG).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our findings demonstrated that the analgesic benefit of (2R,6R)-Hydroxynorketamine is dose dependent, protein analysis suggests that (2R,6R)-HNK analgesic is associated with augmenting GluA1, GluA2, CaMKII, Kv2.1 and a reduction in BDNF protein ratios in hippocampus, decreased spinal cord c-Fos and reduced BNDF at the dorsal root ganglion. (2R,6R)-Hydroxynorketamine also augmented meloxicam analgesia in disk puncture mice. Our finding supports further study of the clinical potential of (2R,6R)-Hydroxynorketamine as a non-opioid analgesic for discogenic back pain.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpain.2025.1574474","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:21:28Z","timestamp":1749705688000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mice"],"prefix":"10.3389","volume":"6","author":[{"given":"Vaskar","family":"Das","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Milejczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Basovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Moric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Kaila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asokumar","family":"Buvanendran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11916-019-0757-1","article-title":"Low back pain, a comprehensive review: pathophysiology, diagnosis, and treatment","volume":"23","author":"Urits","year":"2019","journal-title":"Curr Pain Headache Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.2147\/JPR.S168188","article-title":"Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice","volume":"11","author":"Ho","year":"2018","journal-title":"J Pain Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4212\/cjhp.v68i3.1458","article-title":"Intravenous versus oral acetaminophen for pain: systematic review of current evidence to support clinical decision-making","volume":"68","author":"Jibril","year":"2015","journal-title":"Can J Hosp Pharm"},{"key":"B4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3344\/kjp.2020.33.2.108","article-title":"All about pain pharmacology: what pain physicians should know","volume":"33","author":"Kim","year":"2020","journal-title":"Korean J Pain"},{"key":"B5","doi-asserted-by":"publisher","first-page":"CD013581","DOI":"10.1002\/14651858.CD013581","article-title":"Non-steroidal anti-inflammatory drugs for acute low back pain","volume":"16","author":"van der Gaag","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"m4825","DOI":"10.1136\/bmj.m4825","article-title":"Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis","volume":"372","author":"Ferreira","year":"2021","journal-title":"Br Med J"},{"key":"B7","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"B8","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/j.pain.0000000000002423","article-title":"Efficacy and safety of strong opioids for chronic noncancer pain and chronic low back pain: a systematic review and meta-analyses","volume":"163","author":"Nury","year":"2022","journal-title":"Pain"},{"key":"B9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.4103\/ija.IJA_541_20","article-title":"To compare the analgesic efficacy of two different doses of epidural ketamine in chronic low back-pain patients: a randomised double-blind study","volume":"64","author":"Gupta","year":"2020","journal-title":"Indian J Anaesth"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1080\/09638288.2023.2218652","article-title":"Retrospective review of the efficacy for sublingual ketamine in the treatment of chronic low back pain defined by a cause and central functional pain symptom focused clinical model","volume":"46","author":"Johnson","year":"2024","journal-title":"Disabil Rehabil"},{"key":"B11","article-title":"Ketamine in Acute and Chronic Pain Management","volume-title":"StatPearls","author":"Orhurhu","year":"2023"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/j.pain.2011.03.026","article-title":"Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases","volume":"152","author":"Noppers","year":"2011","journal-title":"Pain"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.talanta.2010.08.005","article-title":"A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome","volume":"82","author":"Moaddel","year":"2010","journal-title":"Talanta"},{"key":"B14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/rapm-2018-000013","article-title":"Efficacy of the ketamine metabolite (2R,6R)-hydroxynorketamine in mice models of pain","volume":"44","author":"Kroin","year":"2019","journal-title":"Reg Anesth Pain Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1213\/ANE.0000000000006590","article-title":"A pharmacological evaluation of the analgesic effect and hippocampal protein modulation of the ketamine metabolite (2R,6R)-hydroxynorketamine in murine pain models","volume":"138","author":"Das","year":"2024","journal-title":"Anesth Analg"},{"key":"B16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1124\/jpet.122.001278","article-title":"Antinociceptive and analgesic effects of (2R,6R)-hydroxynorketamine","volume":"382","author":"Yost","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1744-8069-9-17","article-title":"Preclinical studies of low back pain","volume":"9","author":"Strong","year":"2013","journal-title":"Mol Pain"},{"key":"B18","doi-asserted-by":"publisher","first-page":"894651","DOI":"10.3389\/fpain.2022.894651","article-title":"In vivo mouse intervertebral disc degeneration models and their utility as translational models of clinical discogenic back pain: a comparative review","volume":"3","author":"Tang","year":"2022","journal-title":"Front Pain Res (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"rapm-2019-100839","DOI":"10.1136\/rapm-2019-100839","article-title":"AMP-activated protein kinase (AMPK) activator drugs reduce mechanical allodynia in a mouse model of low back pain","author":"Das","year":"2019","journal-title":"Reg Anesth Pain Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J Neurosci Methods"},{"key":"B21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/AAP.0000000000000622","article-title":"Biochemical and pharmacological characterization of a mice model of Complex regional pain syndrome","volume":"42","author":"Das","year":"2017","journal-title":"Reg Anesth Pain Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0301848","DOI":"10.1371\/journal.pone.0301848","article-title":"Effects of (2R,6R)-hydroxynorketamine in assays of acute pain-stimulated and pain-depressed behaviors in mice","volume":"19","author":"Hillhouse","year":"2024","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2261014\/v1","article-title":"(2r,6R)-hydroxynorketamine restores postsynaptic localization of AMPAR in the prelimbic cortex to provide sustained pain relief","author":"Jin","year":"2022","journal-title":"Res Sq."},{"key":"B24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1124\/molpharm.124.000947","article-title":"Ketamine and major ketamine metabolites function as allosteric modulators of opioid receptors","volume":"106","author":"Gomes","year":"2024","journal-title":"Mol Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/0269881118812095","article-title":"Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine","volume":"33","author":"Highland","year":"2019","journal-title":"J Psychopharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s10194-023-01667-1","article-title":"The potent analgesia of intrathecal 2R, 6R-HNK via TRPA1 inhibition in LF-PENS-induced chronic primary pain model","volume":"24","author":"Liu","year":"2023","journal-title":"J Headache Pain"},{"key":"B27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ejpain.2004.09.002","article-title":"Long-term changes of c-fos expression in the rat spinal cord following chronic constriction injury","volume":"9","author":"Jergova","year":"2005","journal-title":"Eur J Pain"},{"key":"B28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neulet.2008.11.013","article-title":"Spinal cord stimulation induces c-fos expression in the dorsal horn in rats with neuropathic pain after partial sciatic nerve injury","volume":"450","author":"Smits","year":"2008","journal-title":"Neurosci Lett"},{"key":"B29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.30802\/AALAS-JAALAS-22-000064","article-title":"High-dose meloxicam provides improved analgesia in female CD1 mice: a pharmacokinetic and efficacy study","volume":"62","author":"Kim","year":"2023","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3389\/fphar.2018.01340","article-title":"Pathophysiology of NSAID-associated intestinal lesions in the rat: luminal Bacteria and mucosal inflammation as targets for prevention","volume":"9","author":"Colucci","year":"2018","journal-title":"Front Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/cpt.3391","article-title":"A phase 1 assessment of the safety, tolerability, pharmacokinetics and pharmacodynamics of (2R,6R)-hydroxynorketamine in healthy volunteers","volume":"116","author":"Raja","year":"2024","journal-title":"Clin Pharmacol Ther"}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2025.1574474\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T13:43:14Z","timestamp":1749822194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2025.1574474\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":31,"alternative-id":["10.3389\/fpain.2025.1574474"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2025.1574474","relation":{},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"article-number":"1574474"}}